Angle success with ovarian cancer

Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone.

The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening technique to enable the early diagnosis and monitoring of ovarian cancer.

Angle said that ovarian cancer usually had a poor prognosis and the mortality rate was disproportionately high because it lacked any clear early detection or screening test.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

This meant that most cases were not diagnosed until they have reached advanced stages.

"The successful capture and identification of cultured ovarian cancer cells added to blood is significant as it suggests that the Parsortix separation technology may work with all solid tumour cancers," said Angle's Chief Executive, Andrew Newland.

Angle said it had previously demonstrated that Parsortix could capture cultured breast cancer, prostate cancer, lung cancer and colon cancer cells added to blood.

Shares in the firm rose almost 4% following the announcement.